Divi's Laboratories Ltd (Divi’s) develops new processes and produces active pharma ingredients (APIs) & intermediates. The company also conducts FTE/contract research on process development for discovering new compounds for leading companies across the world and partners with them for the supply of APIs. It conducts custom manufacturing of APIs and the production of advanced intermediates.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

The company’s R&D activities focus on process development for APIs and intermediates at its own research center. It also plans to develop synthetic processes for new products and intermediates of Generics. Divi’s has three research centers in Hyderabad, Visakhapatnam and Bhuvanagiri District, Telangana, India with 400 scientists and six new generics. In FY2023, the company spent INR3,005 million on its R&D activities which as a percentage of revenue stood at 3.8% and grew 48.1% YoY.